Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 3, 2006, Pages

  Bergsland, Kristin J ^a   Kelly, Jennifer K ^a   Coe, Brian J ^a   Coe, Fredric L ^b  

^a LithoLink Corporation   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Calgranulin; CD59; Crystallization; Inhibitor; Inter trypsin inhibitor; Kidney calculi; Prothrombin fragment 1

Indexed keywords

CALCIUM OXALATE; CALGRANULIN; CD59 ANTIGEN; INTER ALPHA TRYPSIN INHIBITOR; ISOPROTEIN; PROTEIN PROTHROMBIN FRAGMENT 1; PROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCIUM STONE; CONTROLLED STUDY; CRYSTALLIZATION; DISCRIMINANT ANALYSIS; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROLITHIASIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RISK FACTOR; STONE FORMATION; UNIVARIATE ANALYSIS; URINE; WESTERN BLOTTING;

EID: 33748435188     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00370.2005     Document Type: Article

References (49)

1. Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacy S, Goldfarb D, Grasso M, and Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol 159: 1821-1825, 1998.
2. Asplin JR, Arsenault D, Parks JH, Coe FL, and Hoyer JR. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 53: 194-199, 1998.
3. Atmani F and Khan SR. Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J Am Soc Nephrol 10, Suppl 14: S385-S388, 1999.
4. Atmani F, Lacour B, Drueke T, and Daudon M. Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urol Res 21: 61-66, 1993.
5. Bautista DS, Denstedt J, Chambers AF, and Harris JF. Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem 61: 402-409, 1996.
6. Bergsland KJ, Kinder JM, Asplin JR, Coe BJ, and Coe FL. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol 167: 2372-2376, 2002.
7. Binette J and Binette M. A cationic protein from a urate-calcium oxalate stone: isolation and purification of a shared protein. Scanning Microsc 7: 1107-1110, 1993.
8. Blom AM, Morgelin M, Oyen M, Jarvet J, and Fries E. Structural characterization of inter-α-inhibitor. Evidence for an extended shape. J Biol Chem 274: 298-304, 1999.
9. Dean C, Kanellos J, Pham H, Gomes M, Oates A, Grover P, and Ryall R. Effects of inter-α-inhibitor and several of its derivatives on calcium oxalate crystallization in vitro. Clin Sci (Lond) 98: 471-480, 2000.
10. Dussol B, Geider S, Lilova A, Leonetti F, Dupuy P, Daudon M, Berland Y, Dagorn JC, and Verdier JM. Analysis of the soluble organic matrix of five morphologically different kidney stones. Urol Res 23: 45-51, 1995.
11. Enghild J, Thogersen I, Pizzo S, and Salvesen G. Analysis of inter-α-trypsin inhibitor and a novel trypsin inhibitor, pre-α-trypsin inhibitor, from human plasma. J Biol Chem 264: 15975-15981, 1989.
12. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, and Grynpas M. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111: 607-616, 2003.
13. Glauser A, Hochreiter W, Jaeger P, and Hess B. Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15: 1580-1587, 2000.
14. Hedgepeth RC, Yang L, Resnick MI, and Marengo SR. Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. Am J Kidney Dis 37: 104-112, 2001.
15. Hochstrasser K, Reisinger P, Albrecht GJ, Wachter E, and Schonberger OL. Isolation of acid-resistant urinary trypsin inhibitors by high performance liquid chromatography and their characterization by N-terminal amino-acid sequence determination. Hoppe Seylers Z Physiol Chem 365: 1123-1130, 1984.
16. Hunter MJ and Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem 273: 12427-12435, 1998.
17. Iida S, Peck AB, Johnson-Tardieu J, Moriyama M, Glenton PA, Byer KJ, and Khan SR. Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 10: 986-996, 1999.
18. Johnson RJ. Involvement of complement components in renal disease. Curr Opin Nephrol Hypertens 6: 120-127, 1997.
19. Kinder JM, Clark CD, Coe BJ, Asplin JR, Parks JH, and Coe FL. Urinary stone risk factors in the siblings of patients with calcium renal stones. J Urol 167: 1965-1967, 2002.
20. Knorle R, Schnierle P, Koch A, Buchholz N, Hering F, Seiler H, Ackermann T, and Rutihauser G. Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transformation infrared spectroscopy. Clin Chem 40: 1739-1743, 1994.
21. Kobayashi H, Shibata K, Fujie M, Sugino D, and Terao T. Identification of structural domains in inter-α-trypsin involved in calcium oxalate crystallization. Kidney Int 53: 1727-1735, 1998.
22. Kurata A, Ohi K, Sato K, and Tashiro M. Purification, characterization, and relation to bikunin of rat urinary trypsin inhibitors. J Protein Chem 19: 693-698, 2000.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
24. Lehto T, Honkanen E, Teppo AM, and Meri S. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int 47: 1403-1411, 1995.
25. Levy FL, Adams-Huet B, and Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98: 50-59, 1995.
26. Marengo SR, Resnick M, Yang L, and Chung J. Differential expression of urinary inter-α-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men. J Urol 159: 1444-1450, 1998.
27. Medetognon-Benissan J, Tardivel S, Hennequin C, Daudon M, Drueke T, and Lacour B. Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary decrease in renal stone formers. Urol Res 27: 69-75, 1999.
28. Meri S, Lehto T, Sutton C, Tyynela J, and Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and GPI anchor revealed by laser-desorption mass spectrometric analysis. Biochem J 316: 923-935, 1996.
29. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, and Lachmann PJ. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9, 1990.
30. Mizushima S, Nii A, Kato K, and Uemura A. Gene expression of the two heavy chains and one light chain forming the inter-α-trypsin-inhibitor in human tissues. Biol Pharm Bull 21: 167-169, 1998.
31. Nacken W, Roth J, Sorg C, and Kerkhoff C. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 60: 569-580, 2003.
32. Parks JH and Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30: 85-90, 1986.
33. Petrovan RJ, Govers-Riemslag JW, Nowak G, Hemker HC, Tans G, and Rosing J. Autocatalytic peptide bond cleavages in prothrombin and meizothrombin. Biochemistry 37: 1185-1191, 1998.
34. Pillay SN, Asplin JR, and Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol Renal Physiol 275: F255-F261, 1998.
35. Pletcher CH, Resnick RM, Wei GJ, Bloomfield VA, and Nelsestuen GL. Deglycosylated prothrombin fragment 1. Calcium binding, phospholipid interaction, and self-association. J Biol Chem 255: 7433-7438, 1980.
36. Potempa J, Kwon K, Chawla R, and Travis J. Inter-α-trypsin inhibitor. Inhibition spectrum of native and derived forms. J Biol Chem 264: 15109-15114, 1989.
37. Pugia MJ, Sommer R, Corey P, Anderson L, Gleason S, Jortani SA, Elin RJ, Gopual DL, Valdes R Jr, and Lott JA. The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections. Clin Chim Acta 341: 73-81, 2004.
38. Ryall RL, Grover PK, Stapleton AM, Barrell DK, Tang Y, Moritz RL, and Simpson RJ. The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci (Lond) 89: 533-541, 1995.
39. Salier JP, Rouet P, Raguenez G, and Daveau M. The inter-α-inhibitor family: from structure to regulation. Biochem J 315: 1-9, 1996.
40. Stapleton AM and Ryall RL. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol 75: 712-719, 1995.
41. Stapleton AM, Seymour AE, Brennan JS, Doyle IR, Marshall VR, and Ryall RL. Immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int 44: 817-824, 1993.
42. Stapleton AM, Timme TL, and Ryall RL. Gene expression of prothrombin in the human kidney and its potential relevance to kidney stone disease. Br J Urol 81: 666-671, 1998.
43. Suzuki M, Kobayashi H, Kageyama S, Shibata K, Fujie M, and Terao T. Excretion of bikunin and its fragments in the urine of patients with renal stones. J Urol 166: 268-274, 2001.
44. Teigelkamp S, Bhardwaj R, Meinardus-Hager G, Karas M, and Sorg C. Calcium-dependent complex assembly of the myeloic differentiation proteins MRP-8 and MRP-14. J Biol Chem 266: 13462-13467, 1991.
45. Turnberg D, Botto M, Warren J, Morgan BP, Walport MJ, and Cook HT. CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol 14: 2271-2279, 2003.
46. Verkoelen CF and Schepers MS. Changing concepts in the aetiology of renal stones. Curr Opin Urol 10: 539-544, 2000.
47. Watanabe M, Morita Y, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Morgan BP, Okada N, Okada H, and Matsuo S. CD59 protects rat kidney from complement mediated injury in collaboration with crry. Kidney Int 58: 1569-1579, 2000.
48. Werness PG, Brown CM, Smith LH, and Finlayson B. EQUIL 2: a basic computer program for the calculation of urinary saturation. J Urol 134: 1242-1244, 1985.
49. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, and Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60: 1645-1657, 2001.